Polymyalgia Rheumatica Treatment Market Report and Forecast 2023-2028

According to the report, the global polymyalgia rheumatica treatment market attained a value of USD 193 million in 2022. Aided by the increasing prevalence of polymyalgia rheumatica and the growing geriatric population, the market is projected to further grow at a CAGR of 4.8% between 2023 and 2028 to reach a value of USD 255.52 million by 2028.

Polymyalgia rheumatica (PMR) is an inflammatory disorder that primarily affects the elderly population, causing stiffness, aches, and pain in the shoulders, hips, and neck. The primary treatment for PMR involves the use of corticosteroids to reduce inflammation and alleviate symptoms. In certain circumstances, additional medications like NSAIDs or DMARDs (disease-modifying antirheumatic drugs) may be given.

The increasing prevalence of PMR is one of the primary factors driving the global polymyalgia rheumatica treatment market growth. The rising geriatric population worldwide is more susceptible to inflammatory disorders like PMR, which in turn is expected to lead to a higher demand for effective treatment options.

The growing awareness of PMR and its potential complications is another key factor increasing the polymyalgia rheumatica treatment market share. As healthcare professionals and patients become more aware of the symptoms, diagnosis, and treatment options for PMR, the demand for PMR treatments is likely to increase. Additionally, advancements in diagnostic techniques have facilitated early detection and diagnosis of PMR, further boosting the treatment market.

Moreover, the increasing focus on research and development of novel treatment options for PMR is expected to contribute to the growth of the polymyalgia rheumatica treatment market. Pharmaceutical firms and researchers are actively investigating novel therapeutic strategies, such as targeted immunotherapies, to enhance treatment outcomes and reduce side effects related to corticosteroid-based conventional therapies.

Rising investments towards healthcare infrastructure in various countries is expected to further support the market growth of polymyalgia rheumatica treatment. More countries, particularly those with sizable populations of geriatrics are expanding their healthcare infrastructure to support growing awareness, fast diagnostics, and leading treatment options. Developments of speciality clinics is likely to bolster the market growth of polymyalgia rheumatica treatment in the coming years, with more patients seeking treatments that offer optimum chances of recovery and health stabilisation.

Market Segmentation

The market can be divided based on diagnostic method, drug class, route of administration, end use, and region.

Market Breakup by Diagnostic Method

• Blood Tests
• Imaging Tests

Market Breakup by Drug Class

• Corticosteroids
• Disease-Modifying Anti-Rheumatic Drugs
• Nonsteroidal Anti-Inflammatory Drugs
• Others

Market Breakup by Route of Administration

• Oral
• Parenteral

Market Breakup by End Use

• Hospitals
• Homecare
• Speciality Clinics
• Others

Market Breakup by Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

Competitive Landscape

The report looks into the market shares, plant turnarounds, capacities, investments, and acquisitions and mergers, among other major developments, of the global polymyalgia rheumatica treatment companies. Some of the major key players explored in the report are as follows:

• Sanofi SA
• Apotex Corporation
• GlaxoSmithKline plc
• AbbVie Inc
• Horizon Therapeutics plc
• Others

*The publisher always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.